↓ Skip to main content

Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors

Overview of attention for article published in Frontiers in oncology, October 2023
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (57th percentile)
  • High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

twitter
3 X users

Readers on

mendeley
1 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors
Published in
Frontiers in oncology, October 2023
DOI 10.3389/fonc.2023.1249106
Pubmed ID
Authors

Ping-Chih Hsu, Chun-Yao Huang, Yu-Ching Lin, Suey-Haur Lee, Li-Chung Chiu, Chiao-En Wu, Scott Chih-Hsi Kuo, Jia-Shiuan Ju, Allen Chung-Cheng Huang, Ho-Wen Ko, Chin-Chou Wang, Cheng-Ta Yang

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 October 2023.
All research outputs
#15,447,911
of 26,180,352 outputs
Outputs from Frontiers in oncology
#4,337
of 22,922 outputs
Outputs of similar age
#152,724
of 366,371 outputs
Outputs of similar age from Frontiers in oncology
#110
of 941 outputs
Altmetric has tracked 26,180,352 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,922 research outputs from this source. They receive a mean Attention Score of 3.1. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 366,371 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 57% of its contemporaries.
We're also able to compare this research output to 941 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.